Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18099888 | 0.73 | TSHR (0.43) | ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL5936332 | 0.73 | TSHR (0.43) | ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL6288848 | 0.73 | TSHR (0.43) | ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL21580191 | 0.69 | CHRM5 (0.39) | ALDH1A1KMT2APOLBMAPTTDP1 | |
| SCHEMBL17860841 | 0.68 | MAPT (0.46) | ALDH1A1KMT2AMAPTNPSR1GAA | |
| SCHEMBL9712225 | 0.68 | POLB (0.44) | ALDH1A1KMT2APOLBMAPTTDP1 | |
| SCHEMBL6285030 | 0.68 | ALDH1A1 (0.42) | ALDH1A1KMT2APOLBMAPTTDP1 | |
| SCHEMBL9141580 | 0.67 | — | — | |
| SCHEMBL31634550 | 0.67 | ALDH1A1 (0.47) | ALDH1A1KMT2APOLBMAPTTDP1 | |
| SCHEMBL11689734 | 0.67 | MAPT (0.46) | ALDH1A1KMT2APOLBMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | JACOB GARY S | 2006-05-18 | — | — | US | claimed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20130344476-A1 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-26 | — | — | US | disclosed |
| EP-1958956-B1 | Peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-8501450-B2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | THE CHANCELLORS, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-1951748-B1 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMA (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| EP-1007058-A1 | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. Searle & Co. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999040916-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1998035685-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE AND CO. (US) | 1998-08-20 | — | — | WO | disclosed |
| EP-0386219-A4 | METHOD OF TREATING INFLAMMATION IN MAMMALS UTILIZING KETOBUTYROLACTONES AND FURYLBUTYROLACTONES | — | 1991-11-13 | — | — | EP | disclosed |
| EP-0386219-A1 | METHOD OF TREATING INFLAMMATION IN MAMMALS UTILIZING KETOBUTYROLACTONES AND FURYLBUTYROLACTONES | THERACEL CORPORATION (US) | 1990-09-12 | — | — | EP | disclosed |
| EP-0386219-A1 | METHOD OF TREATING INFLAMMATION IN MAMMALS UTILIZING KETOBUTYROLACTONES AND FURYLBUTYROLACTONES | THERACEL CORPORATION (US) | 1990-09-12 | — | — | EP | disclosed |
| WO-1990001930-A1 | METHOD OF TREATING INFLAMMATION IN MAMMALS UTILIZING KETOBUTYROLACTONES AND FURYLBUTYROLACTONES | THERACEL CORPORATION (US) | 1990-03-08 | — | — | WO | disclosed |
| WO-1990001930-A1 | METHOD OF TREATING INFLAMMATION IN MAMMALS UTILIZING KETOBUTYROLACTONES AND FURYLBUTYROLACTONES | THERACEL CORPORATION (US) | 1990-03-08 | — | — | WO | disclosed |
| US-4883813-A | Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones | AMERICAN BIOTECHNOLOGY COMPANY (US) | 1989-11-28 | — | — | US | disclosed |
| US-4883813-A | Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones | AMERICAN BIOTECHNOLOGY COMPANY (US) | 1989-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | ALDH1A1 2218/4885KMT2A 3611/4885POLB 2945/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | ALDH1A1 2639/4885KMT2A 3519/4885POLB 2212/4885 |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 2476/4885KMT2A 2427/4885POLB 134/4885 |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | HAVCR2, DERA, UGGT1 | ALDH1A1 960/4885KMT2A 4771/4885POLB 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.